Introducing Occlunova: An Implantable Device for Chronic Atrial Fibrillation (AF)

Founded by NLC, OccluNova Advances Development of Implantable LAA Closure Device for Chronic Atrial Fibrillation Patients

Atrial fibrillation (AF), affecting 4.5 million in Europe and over 3 million in the US, has seen a 33% rise in prevalence over two decades, with projections indicating 12 million affected in the US by 2030. AF patients face increased stroke risk due to thrombi formation in the left atrial appendage (LAA).

Currently, oral anticoagulant therapy (OAT) is standard, despite side effects and bleeding risks, costing up to $193,804 annually for bleeding episodes. Existing LAA closure technologies, like the Watchman, pose risks such as pericardial effusions and incomplete occlusion.

OccluNova's innovative technology replaces rigid nitinol frames with a pliable polyurethane balloon, ensuring comprehensive LAA closure regardless of size or shape. The design minimizes thrombus formation risks by eliminating exposed metal.

Chris Pulling, CEO of OccluNova, comments:

"Enabling more patients to safely discontinue OAT by fully occluding the appendage is a significant public health benefit."

Currently in early-stage development with advanced prototypes and successful animal studies, OccluNova aims to transition technology, establish manufacturing, secure Series A funding, refine devices, and commence human trials by Q3/4 2024.

For more information:

OccluNova: Website
Chris Pulling | CEO | Linkedin
cpulling@occlunova.com